Alakesh Alakesh

Alakesh Alakesh

Auto-generated profile, based on publicly available information

Alakesh Alakesh

Department of Materials Science & Engineering, Stanford University, Stanford, CA 94305, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2026 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
SSSamya Sen
Samya Sen
CDChangxin Dong
Changxin Dong
CJCarolyn K. Jons
Carolyn K. Jons
WRWencke Reineking
Wencke Reineking
AAAlakesh Alakesh
Alakesh Alakesh
EAEric A. Appel
Eric A. Appel

5 July 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
ADAndrea I. D'AQuino
Andrea I. D'AQuino
CDChangxin Dong
Changxin Dong
LNLeslee T. Nguyen
Leslee T. Nguyen
JYJerry Yan
Jerry Yan
CJCarolyn K. Jons
Carolyn K. Jons
EAEric A. Appel
Eric A. Appel
Several incretin hormone therapies have been clinically approved and have revolutionized the treatment of diabetes and obesity. Promising therapeutics include semaglutide (Ozempic and Wegovy), an agonist for glucagon-like peptide-1 (GLP-1) receptor, and tirzepatide (Mounjaro), a dual agonist for GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. These molecules help to regulate blood glucose levels, enhance insulin secretion and sensitivity, and reduce appetite. Currently, these treatments require weekly injections, which can be challenging for patients to adhere to. We recently reported the development of an injectable hydrogel depot technology enabling months-long release of semaglutide (Sema). Here, we further develop this technology for improved prolonged release of both Sema and tirzepatide (TZP). In a rat model of diabetes, we show a single administration of hydrogel-based formulations of either Sema or TZP maintained relevant drug levels for over 6 weeks. In these studies, single administrations of long-acting hydrogel-based therapies of Sema or TZP were similarly effective at regulating blood glucose and weight compared to daily injections of either Sema or TZP in standard aqueous vehicles. This hydrogel depot technology is easy to manufacture, injectable, and exhibits excellent biocompatibility, enabling months-long-acting treatments with the potential to improve management of diabetes and weight.

31 March 2026 in Nature Communications
Verified
Journal Article
Open access
EMEmily L. Meany
Emily L. Meany
CWChristian M. Williams
Christian M. Williams
YSYe Eun Song
Ye Eun Song
VDVanessa M. Doulames
Vanessa M. Doulames
AAAlakesh Alakesh
Alakesh Alakesh
EAEric A. Appel
Eric A. Appel
Over 30-40% of 1.5 million annual hand flexor tendon injuries in the United States result in peritendinous adhesions which limit range of motion (ROM) and severely impact quality of life. Currently, no widespread solution exists for adhesion prevention in the delicate space of the digit while allowing full ROM quickly following surgery. Here, we develop dynamically crosslinked, bioresorbable supramolecular hydrogels as easy-to-apply peritendinous adhesion barriers. These hydrogels exhibit long-term stability, injectability, and thermally stable viscoelastic properties that enable simple storage and application. Interactions at the interface of hydrogel and human tissues demonstrate maintenance of a lubricious hydrogel barrier between tissues. Ex vivo studies show cadaveric tendon biomechanics are unimpaired. Application in preclinical rat tendon injury reveals prolonged hydrogel retention and improved functional recovery, including ROM and maximal dorsiflexion. These hydrogels are safe, do not impair tendon healing, and present a scalable intervention to limit peritendinous adhesions with translational potential.

12 December 2025 in Biomaterials
Verified
Journal Article
Closed access
VDVinod Kumar Dorai
Vinod Kumar Dorai
AAAlakesh Alakesh
Alakesh Alakesh
RGRanjitha Guttapadu
Ranjitha Guttapadu
SSShruthi Ksheera Sagar
Shruthi Ksheera Sagar
MVMeghna Ravishankar Valakatte
Meghna Ravishankar Valakatte
SJSiddharth Jhunjhunwala
Siddharth Jhunjhunwala

6 January 2026 in Biomaterials Science
Verified
Journal Article
Open access
PDF file
PGPriya Ganesh
Priya Ganesh
APAlexander N. Prossnitz
Alexander N. Prossnitz
CJCarolyn K. Jons
Carolyn K. Jons
NENoah Eckman
Noah Eckman
AAAlakesh Alakesh
Alakesh Alakesh
EAEric A. Appel
Eric A. Appel
We have developed a simple, scalable, and globally accessible injectable hydrogel platform to improve responses to subunit vaccines against current and emerging pandemic threats.

18 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
CDChangxin Dong
Changxin Dong
ADAndrea I. D’AQuino
Andrea I. D’AQuino
SSSamya Sen
Samya Sen
AAAlakesh Alakesh
Alakesh Alakesh
CJCarolyn K. Jons
Carolyn K. Jons
EAEric A. Appel
Eric A. Appel
Controlled release systems for subcutaneous peptide delivery often exhibit a pronounced initial burst release followed by inadequate maintenance of therapeutic exposure, limiting depot lifetime and increasing pharmacokinetic variability. Here, we engineer a dynamic, injectable hydrogel depot technology for months-long delivery of lipidated peptides. Using semaglutide as a model, we establish a modular formulation framework integrating: (i) formulation-driven tuning of depot mechanics to control release kinetics, (ii) cargo complexation strategies leveraging hydrophobic and multivalent ion-mediated interactions, and (iii) oxidative stabilization through sacrificial antioxidant excipients. We evaluated depot performance by rheology, in vitro cargo release, and in vivo pharmacokinetic and pharmacodynamic studies in rodents. Optimized formulations sustained semaglutide exposure for over six weeks from a single administration with two-fold reduction in peak-to-trough exposure and comparable total bioavailability relative to daily dosing, resulting in improved glucose control, weight regulation, and preservation of pancreatic islet content. These results suggest potential for quarterly dosing in humans. Together, this work establishes integrated and generalizable structure-property-performance relationships that account for cargo–matrix and cargo–excipient interactions across burst, diffusion, and erosion regimes to inform a practical formulation framework for engineering long-acting depots for sustained peptide delivery.